← 返回

TOX 诱导的 lnc-SUMF2-8 通过溶酶体依赖性降解 TCF-1 削弱 CD8⁺ T 细胞的抗肿瘤功能和抗 PD-1 反应

英文原题:TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8(+) T cells via lysosome-dependent degradation of TCF-1.

查看英文原题

TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8(+) T cells via lysosome-dependent degradation of TCF-1.

PubMed 2025/09/10(内容时间) Mol Ther Q1 · IF 11.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CD8+ T细胞耗竭期间TCF-1减少会削弱抗肿瘤活性并降低对免疫检查点抑制剂的应答,但TCF-1如何下调尚不清楚。在此,我们发现,CD8+ T细胞耗竭过程中,转录因子TOX诱导的lnc-SUMF2-8可结合胞质中的TCF-1,并将其引导至溶酶体降解。TCF-1减少会促进前体耗竭T细胞(Tex prog)向中间/效应耗竭T细胞(Tex int/eff)分化,并进一步推动有功能的Tex细胞进入完全功能障碍的终末耗竭状态(Tex term)。

我们证明,T细胞耗竭期间TCF-1减少始于lnc-SUMF2-8依赖的TCF-1蛋白溶酶体降解,随后伴随TCF7 mRNA转录抑制。敲除lnc-SUMF2-8可阻止TCF-1溶酶体降解,在Tex细胞中维持TCF-1水平稳定,从而扩增可应答抗PD-1的Tex prog细胞,并增强功能性CD8+ T细胞持久性。

我们的研究提示,靶向lnc-SUMF2-8可增强抗肿瘤CD8+ T细胞功能,并协同提高抗PD-1治疗和CAR-T 细胞疗法的疗效。

展开英文摘要原文

The reduction of TCF-1 during CD8 + T cell exhaustion leads to attenuated antitumor activity and diminished responsiveness to immune checkpoint inhibitors.

However, how TCF-1 is downregulated remains unclear. Here, we showed that during CD8 + T cell exhaustion, lnc-SUMF2-8, induced by transcription factor TOX, can bind to cytosolic TCF-1 and direct it to the lysosome for degradation. The reduction of TCF-1 promotes Tex prog differentiation into Tex int/eff and further drives functional Tex cells into a fully dysfunctional Tex term state.

We demonstrated that TCF-1 reduction during T cell exhaustion is initiated by lnc-SUMF2-8-dependent lysosomal degradation of TCF-1 protein, followed by transcriptional suppression of TCF7 mRNA. Deletion of lnc-SUMF2-8 blocks lysosomal TCF-1 degradation, which maintains stable TCF-1 levels in Tex cells, thereby expanding the anti-PD-1-responsive Tex prog cells and enhances the persistence of functional CD8 + T cells.

Our findings suggest that targeting lnc-SUMF2-8 could enhance the function of the antitumor CD8 + T cells and synergistically improve the efficacy of anti-PD-1 treatment and CAR-T cell therapies.

论文信息

作者
Jiang P、Chen D、Chen J、Wu J、Zhong Y、Huang S、Mu X、Lu X
第一作者单位
Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Clinical Nutrition Department of Zhongshan Hospital, Fudan University, Shanghai 200000, China.China
通讯作者单位
Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. Electronic address: wangxiaochen@mail.sysu.edu.cn.China
期刊
Molecular therapy : the journal of the American Society of Gene Therapy2025 Dec 3
原文标识
PubMed 40931520 · DOI 10.1016/j.ymthe.2025.09.006